The drug and device industries have a lot hinging on the results of the Nov. 5 U.S. presidential and congressional elections.
Inbrain Neuroelectronics SL closed a $50 million series B financing round to advance clinical trials for its graphene-based brain-computer interface therapeutics platform. The company also secured ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback